Current share price for NEU : $18.920 0.75 (3.81%)
Neuren Pharmaceuticals Limited (NEU), an ASX-listed company, is a biopharmaceutical company developing therapies for brain injury, neurodevelopmental and neurodegenerative disorders. NEU has two key drug products comprising NNZ-2566 and NNZ-2591. NEU has operations in New Zealand, Australia and the USA.
ASX Code | NEU |
Website | http://www.neurenpharma.com |
Industry/Sector | Pharmaceuticals |
Market Cap ($M) | 2,416 |
NEU Share Price | $18.920 |
Day High | $19.420 |
Day Low | $18.620 |
Last Close | $19.670 |
NEU Share Price Movement | $0.75 ( 3.81% ) |
There are no dividends for Neuren Pharmaceuticals Limited (NEU). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Headline | Annoucement date/time+ | Price at announcement+ | Current price+ | Price 7D Avg | Gain/Loss |
---|---|---|---|---|---|
Application for quotation of securities - NEU | 8 Apr 2024 4:26PM | $20.800 | $18.920 | $20.720 | fallen by 9.04% |
Application for quotation of securities - NEU | 12 Mar 2024 2:24PM | $20.740 | $18.920 | $20.720 | fallen by 8.78% |
2023 Results webinar | 29 Feb 2024 4:17PM | $19.360 | $18.920 | $20.720 | fallen by 2.27% |
See all ASX announcements from Neuren Pharmaceuticals Limited (NEU) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
Year to Dec | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
---|---|---|---|---|---|---|---|
2025F | C2 | $90.00 | 66.70% | 21.90 | 0.00 | 0.00% | 0.0% |
2024F | C2 | $54.00 | -55.00% | 36.40 | 0.00 | 0.00% | 0.0% |
2023A | $157.08 | $120.10 | 79,966.70% | 10.30 | 0.00 | 0.00% | 0.0% |
Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
---|---|---|---|---|---|---|---|---|---|---|
2023 A | 2024 F | 2025 F | 2023 A | 2024 F | 2025 F | 2023 A | 2024 F | 2025 F | ||
Mayne Pharma Group (MYX) | $567M | 0.9287 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
Neuren Pharmaceuticals (NEU) | $2,491M | 799.6667 | -0.5504 | 0.6667 | 16.2448 | 36.1296 | 21.6778 | 0.00% | 0.00% | 0.00% |
Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
---|---|---|---|---|
Company | 0.29 | 19.60 | 12.40 | 0.00 |
Market | 0.53 | 15.30 | 1.11 | 1.01 |
Sector | 1.26 | 21.30 | 1.92 | 0.98 |
Name | Position | Start Date |
---|---|---|
Mr Jonathan (Jon) Charles Pilcher | Chief Executive Officer, Managing Director | 14 Jun 2021 |
Dr Trevor D Scott | Non-Executive Director | 5 Mar 2002 |
Ms Dianne Margaret Angus | Non-Executive Director | 1 Jul 2018 |
Dr Jenny Lee Harry | Non-Executive Director | 7 Jul 2018 |
Mr Joseph(Joe) Basile | Non-Executive Director | 2 Mar 2023 |
Mr Patrick Davies | Non-Executive Director, Non-Executive Chairman | 1 Jul 2018 |
Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
---|---|---|---|---|---|---|
13 Sep 2023 | BASILE, Joseph(Joe) | Buy | Direct Shares | 5,000 | $11.990 | $59,950.000 |
14 Jun 2023 | SCOTT, Trevor | Sell | Indirect Shares | 1,175,000 | $13.000 | $15,275,000.000 |
18 Oct 2021 | ANGUS, Dianne | Buy | Direct Shares | 30,000 | $1.977 | $59,316.000 |
See all changes in directors' interest & trades for Neuren Pharmaceuticals Limited (NEU) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
Name | Position |
---|---|
Lauren Frazer | Chief Financial Officer,Company Secretary |
LIZA SQUIRES, M.D. | Chief Medical Officer |
LARRY GLASS | Chief Science Officer |
VIRGINIE DUREZ | Senior Director, Product Development & Project Management |
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neuren Pharmaceuticals Limited (NEU). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
Holding | Name |
---|---|
6,561,977 (5.09%) | Milford Asset Management Limited |
Date | Event |
---|---|
27 February 2025 | Report (Prelim) |
26 August 2024 | Report (Interim) |
Neuren Pharmaceuticals Limited's (NEU) current share price is $18.92. This constitutes a price movement of 8.69% when compared to the share price 7 days ago and is -24.65% below NEU's 12-month high of $25.11 per share. Prices are delayed by at least 20 minutes.
Relative to the previous close share price of $19.67, Neuren Pharmaceuticals Limited's (NEU) current share price of $18.92 constitutes a movement of -$0.75 or -3.81%. Neuren Pharmaceuticals Limited's (NEU) share price movement is -8.69% when compared to 7 days ago and is -24.65% below NEU's 52-week high of $25.11.
Neuren Pharmaceuticals Limited's (NEU) 52-week high is $25.11 which was reached on 28 Dec 2023. Relative to this, NEU's current share price of $18.92 constitutes a -$6.19 or -24.65% drop since that high of $25.11 per NEU share.
Neuren Pharmaceuticals Limited's (NEU) 52-week low is $10.18 which was reached on 26 Oct 2023. Relative to this, NEU's current share price of $18.92 constitutes a $8.74 or 85.85% gain since that low of $10.18 per NEU share.
Over the last 12 months, Neuren Pharmaceuticals Limited (NEU) has a daily average trading volume of 541,844 NEU shares per day.
Neuren Pharmaceuticals Limited (NEU) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for NEU is a ratio that tells you the percentage of Neuren Pharmaceuticals Limited's (NEU) share price that it pays out in dividends each year.
Neuren Pharmaceuticals Limited (NEU) has a franking level of 0%. Franking represents the tax Neuren Pharmaceuticals Limited (NEU) has already paid on any profit it distributes to shareholders as a dividend.
Neuren Pharmaceuticals Limited (NEU) will release its next Annual Report on n/a. Neuren Pharmaceuticals Limited's (NEU) last annual report was released on 27 Apr 2023. Click here to view Neuren Pharmaceuticals Limited's (NEU) last annual report.
Neuren Pharmaceuticals Limited (NEU) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), Cochlear Limited (COH), ResMed Inc. (RMD), and Fisher & Paykel Healthcare Corporation Limited (FPH).
The price-to-earnings (P/E) ratio for Neuren Pharmaceuticals Limited (NEU) is 19.6. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Neuren Pharmaceuticals Limited's (NEU) share price to its earnings per NEU share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.